Deucravacitinib in Plaque Psoriasis After Inadequate Response to Apremilast: Phase 3 POETYK Analysis

Abstract Introduction Moderate-to-severe plaque psoriasis can be difficult to treat; not all patients respond to treatment. POETYK PSO-1 and PSO-2 were 52-week, phase 3, multinational, double-blinded trials in plaque psoriasis. We determined deucravacitinib efficacy in PSO-1/PSO-2 patients who did n...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	April W. Armstrong, Richard B. Warren, Howard Sofen, Lynda Spelman, Misti Linaberry, Brandon Becker, Ying-Ming Jou, Carolin Daamen, Alexa B. Kimball
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	Adis, Springer Healthcare 2025-12-01
Saila:	Dermatology and Therapy
Gaiak:	Clinical trials Deucravacitinib Psoriasis Psoriasis treatment Tyrosine kinase 2 inhibitor
Sarrera elektronikoa:	https://doi.org/10.1007/s13555-025-01606-9
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!